The Pharmaceutical Journal
Vol 278 No 7435 p68
20 January 2007

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Pexelizumab stumbles in reperfusion trial

Pexelizumab, a humanised monoclonal antibody that binds the C5 component of complement, has failed to improve 30-day mortality for patients with acute ST-elevation myocardial infarction when used as an adjunct to percutaneous transluminal coronary intervention (JAMA 2007;297:43).

The drug had shown promise in earlier studies (PJ, 7 December 2002, p803 and 13 December 2003, p806).